Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Regorafenib, RRM2, and Melanoma Progression
2026-09-15
The 2024 iScience study identifies RRM2 as a mechanistic downstream target through which Regorafenib suppresses melanoma cell growth, invasion, and metastasis. Its combination of RNA sequencing, functional perturbation, pathway analysis, and in vivo validation provides a useful framework for studying multikinase inhibitor responses beyond angiogenesis.
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-14
Borchert et al. linked homologous recombination repair defects, including BAP1-associated BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their integrated cell-line and clinical-sample strategy supports molecular stratification of mesothelioma while emphasizing that the findings remain preclinical and require prospective validation.
Ruxolitinib, DRP1, and ATC Cell Death
2026-09-14
A 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, apoptosis, and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its in vitro and in vivo findings position transcriptional control of mitochondrial dynamics as an important component of ruxolitinib activity in this aggressive tumor context.
Nocodazole as a Translational Cell-Cycle Probe
2026-09-13
Nocodazole is more than a mitotic-arrest reagent: its reversible control of β-tubulin and microtubule dynamics can help translational researchers connect cytoskeletal state, mitotic progression, cap-dependent translation, and cancer phenotypes. This article presents a mechanism-led framework for experimental validation, assay design, reagent selection, and preclinical interpretation.
Ganetespib: From Hsp90 Mechanism to Assay Insight
2026-09-12
Ganetespib and STA-9090 offer a powerful framework for studying Hsp90-dependent tumor biology. This article connects its cancer research applications with a landmark norovirus secretion study to show how causal, orthogonal assay design can improve mechanistic interpretation.
Troglitazone: From PPARγ Biology to SPP1 Strategy
2026-09-11
Troglitazone offers a useful PPARγ-centered research entry point for connecting lipid and glucose metabolism with tumor-myeloid biology. This thought-leadership article translates SPP1-focused macrophage screening into a rigorous strategy for testing whether nuclear-receptor perturbation can reprogram SPP1-high tumor-associated macrophages without confusing hypothesis with established evidence.
ARCA Cy5 EGFP mRNA: A Dual-Readout Benchmark
2026-09-11
ARCA Cy5 EGFP mRNA (5-moUTP) separates mRNA uptake from productive protein expression in mammalian cells. This article shows how to use its dual fluorescence design to make delivery-system comparisons more mechanistically informative, drawing on nanoparticle stability research.
IPR-803: From uPAR Binding to Stromal Remodeling
2026-09-10
IPR-803 is a urokinase receptor inhibitor that connects direct uPAR–uPA blockade with invasion, angiogenesis, and pancreatic tumor-stroma research. This guide translates its biochemical, cellular, and nanomedicine evidence into practical assay decisions.
DHHC9–STRN4 Palmitoylation Drives Cancer Metastasis
2026-09-10
This study identifies DHHC9-mediated STRN4 palmitoylation as a regulatory mechanism that activates YAP and promotes adenocarcinoma migration and metastasis. Its combination of genetic, proteomic, functional, and pharmacological evidence positions the DHHC9–STRN4–YAP axis as a promising preclinical framework for investigating palmitoylation-directed cancer therapies.
Ibotenic Acid for Neural Circuit Models
2026-09-09
Ibotenic acid is a practical NMDA receptor agonist for probing excitotoxic circuit disruption, focal neuronal injury, and glutamatergic signaling modulation. This guide connects formulation control with the brain-to-spinal pain circuitry reported in a Cell Reports study, while emphasizing assay controls, interpretation limits, and troubleshooting.
Biotin-XX Tyramide: From Signal to Spatial Insight
2026-09-09
Biotin-XX Tyramide Reagent connects high-sensitivity tyramide signal amplification with membrane-restricted spatial biology. This article examines its mechanism, experimental controls, translational applications, and the practical implications of neurotransmitter interference in HRP-mediated proximity labeling.
AICAR Phosphate: AMPK Assay Workflows
2026-09-08
AICAR phosphate, also known as Acadesine, connects AMPK pathway activation with apoptosis-focused workflows in B-CLL and exploratory mitochondrial studies. This guide combines dose-ranging, caspase and cytochrome c readouts, storage guidance, and a carefully bounded extension to mechanically loaded periodontal models.
HyperScript RT SuperMix for qPCR: Hypoxia-to-qPCR
2026-09-08
HyperScript RT SuperMix for qPCR supports reliable cDNA synthesis from structured or scarce RNA. This article translates recent SQOR–ferroptosis findings in hypoxic pancreatic cancer into practical reverse-transcription and qPCR assay decisions.
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-09-07
This Advanced Science study identifies striatal D2 receptor-expressing medium spiny neurons as a cell-type-specific driver of excessive self-grooming and digging after Neuroligin 1 loss. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, the work connects D2-MSN hyperactivity with PKC overactivation and provides a mechanistic framework for studying restricted and repetitive behaviors.
Tomivosertib and Human DRG Hyperexcitability
2026-09-07
The reference study provides direct human evidence that MNK inhibition can rapidly and reversibly suppress spontaneous activity in cultured dorsal root ganglion neurons obtained from patients with radiculopathy. By pairing electrophysiology with eIF4E Ser209 target-engagement data, it connects MNK-eIF4E signaling to ectopic sensory-neuron activity relevant to neuropathic pain.
7828 records 8/522 page Previous Next First page 上5页 678910 下5页 Last page